Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical

The healthcare giant said the addition of the medical-device maker would expand its MedTech cardiovascular portfolio.

Johnson & Johnson to Buy Shockwave Medical in $13.1 Billion Deal

Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.

Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal

Johnson & Johnson (NYSE: JNJ ) is buying medical device company Shockwave Medical (NASDAQ: SWAV ) for $13.1 billion. Shockwave makes devices that perform Intravascular Lithotripsy.

SWAV Stock Alert: Shockwave Medical Lands Big Buyer in Johnson & Johnson

Johnson & Johnson will pay $13.1 billion, or $335 a share, for Shockwave Medical, which has soared in 2024 in part on takeover speculation.

Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion

Shockwave Medical Inc (NASDAQ: SWAV) is in the green today after Johnson & Johnson (NYSE: JNJ) said it will buy the medical device maker for $12.5 billion. Shockwave Medical stock priced at a premium The all-cash agreement values each share of Shockwave Medical at $335 – a 5.0% premium on their previous close.

Johnson & Johnson to buy Shockwave Medical for $12.5 billion

Johnson & Johnson is buying the medical-devices maker for a total enterprise value of about $13.1 billion.

Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.

Johnson & Johnson JNJ, -1.14% has agreed to acquire Shockwave Medical Inc. SWAV, -0.23% in an all-cash deal with an enterprise value of about $13 billion, the companies said Friday. J&J will pay $335 a share in cash, equal to a 4.7% premium over Shockwave's closing price Thursday at $319.99.

Johnson & Johnson to acquire Shockwave Medical in $13.1 billion deal

Johnson & Johnson will buy medical device maker Shockwave Medical for about $12.5 billion, the companies said on Friday, helping the healthcare conglomerate boost its portfolio of medical devices.

Johnson & Johnson to buy Shockwave Medical for $12.5 bln

NEW BRUNSWICK, N.J. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction was approved by both companies' boards of directors. The a.

Johnson & Johnson to Acquire Shockwave Medical

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash. TRC Capital Investment's offer price of $151.23 per share is approximately 4.12% lower than the $157.73 closing share price of Johnson & Johnson's common stock on April 2,.

Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

ARK Genomic Revolution Multi-Sector ETF

ROBO Global Healthcare Technology and Innovation ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.

Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

Bristol-Myers

Merck

Pfizer

Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.

Becton, Dickinson and Co.

Looking for Dividend aristocrats trading at their 52-week lows? If so, you've come to the right place.

Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Apple

Amgen

Amazon

Boeing

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Coca-Cola

McDonald's

Microsoft

NIKE

UnitedHealth Group

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.”–Dow Jones & Co. The highest-yield 10 stocks are April's Dogs of the Dow: GS, JNJ, KO, AMGN, CSCO, IBM, CVX, DOW, MMM, and VZ. They only averaged a 3.97% annual yield, as prices. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated April net gains ranged from 11.38%-26.62%, topped by BA 3/28/24.

April Dogs Of The Dow: Buy 1, Watch 4

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson announced today that it is collaborating with more than 100 community-led health organizations supporting historically marginalized communities across the United States — building on the Company's multiyear, multimillion-dollar efforts to improve health equity. Studies have shown that people of color in the U.S. face disparities in access to health care, quality of care, and mortality when compared to their White counterparts.1 And des.

Johnson & Johnson Expands Commitment to Advance Health Equity

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14th, at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com. Th.

Johnson & Johnson to Participate in the BofA Securities Health Care Conference

Costco

W.W. Grainger

Kimberly-Clark

Procter & Gamble

Parker-Hannifin

Raytheon Technologies

Southern Company

Sysco

Travelers

12 expected dividend increases in April 2024. Dividend growth is crucial for reaching financial freedom and combating high inflation.

12 Dividend Increases Expected In April 2024

Procter & Gamble, Johnson & Johnson Among 10 Dividend Growth Companies Announcing Increases In First Half Of April

It's always a good time to invest in wonderful companies. Johnson & Johnson is delivering strong financial results from an established lineup of businesses.

2024 S&P 500 Bull Market: 2 Unstoppable Growth Stocks to Buy Right Now

AbbVie

Medtronic

Now that it's focused on just medical technology and pharmaceuticals, Johnson & Johnson's pace of annual dividend raises could accelerate. Medtronic is the largest publicly traded medical device manufacturer, and it offers a 3.3% yield at recent prices.

3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade

Johnson & Johnson settles a consumer protection lawsuit for $75 million, a significant reduction from the initial demand of $6 billion. The company is facing nearly 60,000 lawsuits from ex-talc users claiming that the powder caused their cancer. A US District Judge is allowing the company to contest evidence linking its talc powder to cancer, providing an opportunity for new arguments in its defense.

News for Johnson & Johnson Stock (JNJ)